Beijing Xunsheng Biomedical Research

Beijing Xunsheng Biomedical Research (also known as Aeonvital) is an innovative Chinese biotechnology company founded in 2021 and headquartered in Daxing District, Beijing. The company is dedicated to developing novel individualized tumor immunotherapies and nucleic acid drugs, focusing on tumor-infiltrating lymphocyte (TIL) therapies and therapeutic DNA/mRNA vaccines. Leveraging its proprietary TILAmp™ cell expansion and LentiVae™ lentiviral gene modification platforms, Aeonvital has advanced its lead TIL candidate, ReT01 ACT, into Phase 2 clinical trials for advanced cervical cancer and other solid tumors. Additionally, the company utilizes its engineered bacterial vector and sequence design platforms to develop therapeutic vaccines, including its lead DNA-based HPV vaccine, AVL-101, which is currently in Phase 1 clinical testing. Aeonvital has established a robust pipeline targeting various cancers and infectious diseases, supported by multiple rounds of venture backing from prominent Chinese investors.